209 related articles for article (PubMed ID: 19718394)
1. Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures.
Iwamoto J; Sato Y; Uzawa M; Takeda T; Matsumoto H
Yonsei Med J; 2009 Aug; 50(4):474-81. PubMed ID: 19718394
[TBL] [Abstract][Full Text] [Related]
2. Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures.
Iwamoto J; Uzawa M
Clin Rheumatol; 2016 Jan; 35(1):205-12. PubMed ID: 25367347
[TBL] [Abstract][Full Text] [Related]
3. Effects of alendronate or alfacalcidol on bone metabolic indices and bone mineral density in patients with ophthalmologic disease treated with glucocorticoid.
Ikeda T; Maruyama K; Kaji H; Akagi M
Mod Rheumatol; 2014 Jul; 24(4):671-6. PubMed ID: 24313921
[TBL] [Abstract][Full Text] [Related]
4. Differences of therapeutic effects on regional bone mineral density and markers of bone mineral metabolism between alendronate and alfacalcidol in Japanese osteoporotic women.
Takata S; Abbaspour A; Yonezu H; Yasui N
J Med Invest; 2007 Feb; 54(1-2):35-40. PubMed ID: 17380012
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the effects of alendronate and alfacalcidol on bone mineral density around the femoral implant and in the lumbar spine after total hip arthroplasty.
Iwamoto N; Inaba Y; Kobayashi N; Ishida T; Yukizawa Y; Saito T
J Bone Joint Surg Am; 2011 Jul; 93(13):1203-9. PubMed ID: 21776573
[TBL] [Abstract][Full Text] [Related]
6. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
Ringe JD; Farahmand P; Schacht E; Rozehnal A
Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
[TBL] [Abstract][Full Text] [Related]
7. The safety and efficacy of early-stage bi-weekly alendronate to improve bone mineral density and bone turnover in chinese post-menopausal women at risk of osteoporosis.
You L; Sheng ZY; Chen JY; Pan L; Chen L
J Int Med Res; 2011; 39(1):302-10. PubMed ID: 21672334
[TBL] [Abstract][Full Text] [Related]
8. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
Jacobs JW; de Nijs RN; Lems WF; Geusens PP; Laan RF; Huisman AM; Algra A; Buskens E; Hofbauer LC; Oostveen AC; Bruyn GA; Dijkmans BA; Bijlsma JW
J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
[TBL] [Abstract][Full Text] [Related]
9. Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study.
Majima T; Shimatsu A; Komatsu Y; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
J Bone Miner Metab; 2009; 27(2):168-74. PubMed ID: 19183836
[TBL] [Abstract][Full Text] [Related]
10. Effect of alendronate on bone mineral density and bone turnover markers in post-gastrectomy osteoporotic patients.
Iwamoto J; Uzawa M; Sato Y; Takeda T; Matsumoto H
J Bone Miner Metab; 2010 Mar; 28(2):202-8. PubMed ID: 19690798
[TBL] [Abstract][Full Text] [Related]
11. Effects of alendronate and alfacalcidol on bone in patients with myasthenia gravis initiating glucocorticoids treatment.
Lv F; Guan Y; Ma D; Xu X; Song Y; Li L; Jiang Y; Wang O; Xia W; Xing X; Li M
Clin Endocrinol (Oxf); 2018 Mar; 88(3):380-387. PubMed ID: 29266368
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
Clin Rheumatol; 2007 Feb; 26(2):161-7. PubMed ID: 16565894
[TBL] [Abstract][Full Text] [Related]
13. Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis.
Iwamoto J; Sato Y; Uzawa M; Takeda T; Matsumoto H
Yonsei Med J; 2008 Feb; 49(1):119-28. PubMed ID: 18306478
[TBL] [Abstract][Full Text] [Related]
14. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
15. Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol.
Takeda S; Kaneoka H; Saito T
Mod Rheumatol; 2008; 18(3):271-6. PubMed ID: 18427724
[TBL] [Abstract][Full Text] [Related]
16. Potential of alfacalcidol for reducing increased risk of falls and fractures.
Ringe JD; Schacht E
Rheumatol Int; 2009 Aug; 29(10):1177-85. PubMed ID: 19159932
[TBL] [Abstract][Full Text] [Related]
17. Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia.
Gorai I; Hattori S; Tanaka Y; Iwaoki Y
J Bone Miner Metab; 2012 May; 30(3):349-58. PubMed ID: 22130786
[TBL] [Abstract][Full Text] [Related]
18. Fall Prevention and Anti-Osteoporosis in Osteopenia Patients of 80 Years of Age and Older: A Randomized Controlled Study.
Zhou J; Liu B; Qin MZ; Liu JP
Orthop Surg; 2020 Jun; 12(3):890-899. PubMed ID: 32495521
[TBL] [Abstract][Full Text] [Related]
19. Five-year alendronate treatment outcome in older postmenopausal Japanese women with osteoporosis or osteopenia and clinical risk factors for fractures.
Iwamoto J; Miyata A; Sato Y; Takeda T; Matsumoto H
Ther Clin Risk Manag; 2009; 5():773-9. PubMed ID: 19851524
[TBL] [Abstract][Full Text] [Related]
20. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
Jiang Y; Li M; Xia W; Xing X; Yu W; Tian J; Meng X; Zhou X
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(18):1254-6. PubMed ID: 12425805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
